{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:33Z","timestamp":1781179113588,"version":"3.54.1"},"reference-count":31,"publisher":"Scientific Scholar","issue":"04","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer ranks as the eighth leading cause of cancer-related mortality in Thailand, exhibiting an average annual percent increase in incidence rates of 2.7%. Abiraterone acetate, an active prodrug of abiraterone, exhibits potent inhibitory activity against the enzyme CYP17A1, a crucial component in the androgenic biosynthetic cascade. This study was designed to evaluate the safety and efficacy of generic abiraterone (Abiratred) in treating metastatic prostate cancer within a real-world, retrospective observational context.<\/jats:p>\n                  <jats:p>Thirty-five patients diagnosed with metastatic prostate cancer who underwent abiraterone treatment at Siriraj Hospital in Thailand were enrolled in the study. Data encompassing demographics, medical history, general examination, vital signs, comorbidities, health status, and prostate cancer-related characteristics were collected. The primary outcome measure was the prostate-specific antigen (PSA) response rate (defined as a \u2265 50% decrease in PSA levels from baseline), and secondary outcomes encompassed assessing PSA progression-free survival (PFS), disease control rate (DCR), and evaluating safety.<\/jats:p>\n                  <jats:p>Among the 35 patients, 23 (65.7%) exhibited a PSA response. The median PSA PFS at 6 months was 65.6% (21 out of 35 patients). The DCR was determined to be 71.4% (25 out of 35 patients), with 19 (54.3%) patients experiencing stable disease and 6 (17.1%) patients showing a partial response. Adverse events were observed in 5 (14.3%) patients, but there were no deaths related to abiraterone.<\/jats:p>\n                  <jats:p>This real-world study provides evidence that generic abiraterone (Abiratred) is both well-tolerated and effective for patients with advanced or metastatic prostate cancer, making it a promising option in real-world clinical settings.<\/jats:p>","DOI":"10.1055\/s-0045-1809350","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T18:48:33Z","timestamp":1750445313000},"page":"820-826","source":"Crossref","is-referenced-by-count":0,"title":["A Single-Center, Retrospective, Real-World, Observational Clinical Study to Evaluate the Safety and Efficacy of Abiraterone (Abiratred) in Patients with Metastatic Prostate Cancer"],"prefix":"10.25259","volume":"14","author":[{"given":"Pongwut","family":"Danchaivijitr","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2003-9127","authenticated-orcid":false,"given":"Anita","family":"Archwamety","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concord","family":"Wongkraisri","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"P Rawla","year":"2019","journal-title":"World J Oncol"},{"issue":"09","key":"ref2","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/cncr.32733","article-title":"Incidence and disease burden of prostate cancer from 1990 to 2017: results from the Global Burden of Disease Study 2017","volume":"126","author":"Z Zhai","year":"2020","journal-title":"Cancer"},{"issue":"03","key":"ref3","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1186\/s12885-018-5102-2","article-title":"Differences in prostate tumor characteristics and survival among religious groups in Songkhla, Thailand","volume":"18","author":"C S Alvarez","year":"2018","journal-title":"BMC Cancer"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12014-020-09305-7","article-title":"Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management","volume":"17","author":"C Tonry","year":"2020","journal-title":"Clin Proteomics"},{"issue":"04","key":"ref6","first-page":"1","article-title":"Current and future burden of prostate cancer in Songkhla, Thailand: analysis of incidence and mortality trends from 1990 to 2030","volume":"4","author":"C S Alvarez","year":"2018","journal-title":"J Glob Oncol"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","article-title":"Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021","volume":"80","author":"H Van Poppel","year":"2021","journal-title":"Eur Urol"},{"issue":"03","key":"ref8","first-page":"365","article-title":"Mechanisms of resistance in castration-resistant prostate cancer (CRPC)","volume":"4","author":"T Chandrasekar","year":"2015","journal-title":"Transl Androl Urol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.2147\/OTT.S159777","article-title":"Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer","volume":"11","author":"K Wang","year":"2018","journal-title":"OncoTargets Ther"},{"issue":"28","key":"ref10","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"G Attard","year":"2008","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 3.2024","volume":"22","author":"E M Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"K Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1634\/theoncologist.2014-0167","article-title":"Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"19","author":"R J Auchus","year":"2014","journal-title":"Oncologist"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/JGO.19.00341","article-title":"Low-dose abiraterone in metastatic prostate cancer: is it practice changing? Facts and facets","volume":"6","author":"A Patel","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"C J Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"C J Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopha.2018.02.067","article-title":"Abiraterone acetate in the treatment of prostate cancer","volume":"101","author":"A Thakur","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"100518","DOI":"10.1016\/j.esmoop.2022.100518","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer","volume":"7","author":"R Kanesvaran","year":"2022","journal-title":"ESMO Open"},{"issue":"13","key":"ref19","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1002\/cam4.3101","article-title":"Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: real-world experience in the Southeast Asian cohort","volume":"9","author":"J Lim","year":"2020","journal-title":"Cancer Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fphar.2016.00123","article-title":"Very early PSA response to abiraterone in mCRPC patients: a novel prognostic factor predicting overall survival","volume":"7","author":"G Facchini","year":"2016","journal-title":"Front Pharmacol"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdt581","article-title":"Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer","volume":"25","author":"R Leibowitz-Amit","year":"2014","journal-title":"Ann Oncol"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12094-018-1921-5","article-title":"Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis","volume":"21","author":"M Koninckx","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"656146","DOI":"10.3389\/fonc.2021.656146","article-title":"Real-world data on outcomes in metastatic castrate-resistant prostate cancer patients treated with abiraterone or enzalutamide: a regional experience","volume":"11","author":"R Raju","year":"2021","journal-title":"Front Oncol"},{"issue":"06","key":"ref24","first-page":"296","article-title":"Medication adherence, treatment patterns, and dose reduction in patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate or enzalutamide","volume":"10","author":"A S Behl","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/GO.20.00505","article-title":"Consensus for treatment of metastatic castration-sensitive prostate cancer: report from the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)","volume":"7","author":"F C Maluf","year":"2021","journal-title":"JCO Glob Oncol"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/COC.0b013e3182a790ce","article-title":"Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors","volume":"38","author":"G Procopio","year":"2015","journal-title":"Am J Clin Oncol"},{"issue":"48","key":"ref27","doi-asserted-by":"crossref","first-page":"84572","DOI":"10.18632\/oncotarget.20028","article-title":"Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials","volume":"8","author":"R B Moreira","year":"2017","journal-title":"Oncotarget"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2014.03.020","article-title":"External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone","volume":"66","author":"P Ravi","year":"2014","journal-title":"Eur Urol"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.juro.2018.03.125","article-title":"The IMAAGEN study: effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer","volume":"200","author":"C J Ryan","year":"2018","journal-title":"J Urol"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11523-021-00807-4","article-title":"Real-world safety and efficacy outcomes with abiraterone acetate plus prednisone or prednisolone as the first- or second-line treatment for metastatic castration-resistant prostate cancer: data from the Prostate Cancer Registry","volume":"16","author":"A Bjartell","year":"2021","journal-title":"Target Oncol"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1186\/s12885-017-3755-x","article-title":"Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter \u201creal life\u201d study","volume":"17","author":"L Cindolo","year":"2017","journal-title":"BMC Cancer"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1809350.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:13:21Z","timestamp":1781176401000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/a-single-center-retrospective-real-world-observational-clinical-study-to-evaluate-the-safety-and-efficacy-of-abiraterone-abiratred-in-patients-with-metastatic-prostate-cancer\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":31,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2025,12,29]]},"published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0045-1809350","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}